(AZD9291) and Bevacizumab versus Osimertinib
(AZD9291) Alone as First-Line Treatment for Patients
with Metastatic EGFR-Mutant Non-Small Cell Lung
Cancer (NSCLC)
The University of Virginia Comprehensive Cancer Center seeks participants ages 18 and over with advanced metastatic EGFR-Mutant non-small cell lung cancer. In this study, you will be randomly assigned to a study group. Depending on your assigned group, you will either receive osimertinib (AZD9291), an EGFR inhibitor, alone, or you will get a combination of osimertinib (AZD9291) and bevacizumab, a VEGF inhibitor, until your cancer returns or spreads, you experience unacceptable side effects, or until you decide to come off the study. This study approach may be effective by controlling your cancer for longer than the standard of care and possibly helping you live longer. This study may also help doctors learn things that can help other people in the future.
Before you begin the study, your doctor will review the results of your exams, tests, and procedures. This helps your doctor decide if it is safe for you to take part in the study. If you join the study, you will have more exams, tests, and procedures to closely monitor your safety and health. Most of these are included in the usual care you would get even if you were not in a study. Blood and archived tissue sample collection is optional and being collected for research purposes. If you do not want to contribute blood or tissue samples, you will still be allowed to participate in the study.
Your doctor will continue to follow your condition for 10 years from the date you registered to the study and watch you for side effects. After you finish your treatment, you will be contacted for follow up every 3 months by attending office visits, or by phone if in-person visits are not already being done.
Additional information found here: https://www.clinicaltrials.gov/study/NCT04181060?titles=Randomized%20Ph…
No Compensation